Evidence map›Paper›PMID 32059986›Full record

ArticleOphthalmology. Retina2020

Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity.

Abdualrahman E Hamad, Omar Moinuddin, Michael P Blair, Sidney A Schechet, Michael J Shapiro, Polly A Quiram, Danny A Mammo, Audina M Berrocal, Supalert Prakhunhungsit, Linda A Cernichiaro-Espinosa and 19 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in Ophthalmology. Retina, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07427719 (Children Treated for Retinopathy of Prematurity - Study of Visual Function and Retinal Structure), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07427719 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Children Treated for Retinopathy of Prematurity - Study of Visual Function and Retinal Structure

TypeobservationalSponsorOslo University HospitalRan2026 to 2029Enrolled140ConditionsRetinopathy of Prematurity (ROP), Prematurity Complications, Cerebral Visual Impairment, Visual Field Defect
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 83 citations in OpenAlex.

  1. Risk factors and timing of ocular complications after screening for retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Persistent avascular retina in retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 15 institutions in 1 country.

Abdualrahman E HamadRetina and Vitreous of Texas, Houston, Texas; Henry Ford Health System, Detroit, Michigan.
Omar MoinuddinKellogg Eye Center, University of Michigan School of Medicine, Ann Arbor, Michigan.
Michael P BlairDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois; Retina Consultants, Ltd, Chicago, Illinois.
Sidney A SchechetDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois.
Michael J ShapiroDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois; Retina Consultants, Ltd, Chicago, Illinois.
Polly A QuiramVitreoRetinal Surgery, PA, Minneapolis, Minnesota; Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
Danny A MammoDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
Audina M BerrocalBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Supalert PrakhunhungsitBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Linda A Cernichiaro-EspinosaBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Shizuo MukaiDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts; Pediatric Retina Surgery Service, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Yoshihiro YonekawaDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts; Pediatric Retina Surgery Service, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Cindy UngDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
Eric R HolzRetina and Vitreous of Texas, Houston, Texas.
C Armitage HarperAustin Retina Associates, Austin, Texas.
Ryan C YoungAustin Retina Associates, Austin, Texas.
Cagri G BesirliKellogg Eye Center, University of Michigan School of Medicine, Ann Arbor, Michigan.
Aaron NagielUSC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California; The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California.
Thomas C LeeUSC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California; The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California.
Mrinali P GuptaDepartment of Ophthalmology, Weill Cornell Medical College, New York, New York.
Mark K WalshRetina Associates, Tucson, Arizona.
Joseph A KhawlyRetina and Vitreous of Texas, Houston, Texas.
J Peter CampbellCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Andres KychenthalKYDOFT Foundation, Santiago, Chile.
Eric D NudlemanShiley Eye Institute, University of California San Diego School of Medicine, San Diego, California.
Josh E RobinsonPalmetto Retina Center, West Columbia, South Carolina.
Mary Elizabeth HartnettJohn A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, Utah.
Charles M CalvoJohn A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, Utah.
Emmanuel Y ChangRetina and Vitreous of Texas, Houston, Texas. Electronic address: emanmdphd@gmail.com.
Massachusetts Eye and Ear Infirmary · USRetina Consultants of Texas · USUniversity of Chicago · USUniversity of Miami · USTexas Retina Associates (United States) · USUniversity of Minnesota · USUniversity of Southern California · USUniversity of Utah · USW.K. Kellogg Foundation · USCornell University · USHenry Ford Health System · USOregon Health & Science University · USPalmetto Retina Center · USRetina Associates · USSmith-Kettlewell Eye Research Institute · US

Funding

Proteomics CoreP30EY010572 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CATHERINE W MORGANS · 1995 to 2026
$19.4M
University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Behrad Noudoost · 2005 to 2026
$14.6M
Clinical and Genetic Analysis of Retinopathy of PrematurityR01EY019474 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CAMPBELL, JOHN PETER · 2010 to 2020
$7.0M
Mentored Vision Clinician-Scientist Program at OHSUK12EY027720 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI David Huang · 2018 to 2026
$2.2M
Clinical and genetic analysis of retinopathy of prematurityR01HD107493 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI CAMPBELL, JOHN PETER · 2021 to 2023
$1.8M
Role of PDLIM1 in Retinal Vascular Leakage and ProliferationK08EY028999 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NUDLEMAN, ERIC D · 2018 to 2020
$713k
NEI NIH HHS K08 EY028999NEI NIH HHS K12 EY027720NEI NIH HHS P30 EY010572NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY019474NICHD NIH HHS R01 HD107493
6 · The paper itself

Abstract

purposeTo investigate late retinal findings and complications of eyes with a history of retinopathy of prematurity (ROP) that did not meet treatment criteria and did not receive treatment during infancy.

designRetrospective, nonconsecutive, noncomparative, multicenter case series.

participantsThree hundred sixty-three eyes of 186 patients.

methodsData were requested from multiple providers on premature patients with a history of ROP and no treatment during infancy who demonstrated late retinal findings or complications and included age, gender, gestational age and weight, zone and stage at infancy, visual acuity, current retina vascularization status, vitreous character, presence of peripheral retinal findings such as lattice retinal tears and detachments (RDs), retinoschisis, and fluorescein findings.

main outcome measuresRate of RDs and factors conferring a higher risk of RDs.

resultsThe average age was 34.5 years (range, 7-76 years), average gestational age was 26.6 weeks (range, 23-34 weeks), and average birth weight was 875 g (range, 425-1590 g). Findings included lattice in 196 eyes (54.0%), atrophic holes in 126 eyes (34.7%), retinal tears in 111 eyes (30.6%), RDs in 140 eyes (38.6 %), tractional retinoschisis in 44 eyes (11.9%), and visible vitreous condensation ridge-like interface in 112 eyes (30.5%). Fluorescein angiography (FA) was performed in 113 eyes, of which 59 eyes (52.2%) showed leakage and 16 eyes (14.2%) showed neovascularization. Incomplete vascularization posterior to zone 3 was common (71.6% of eyes). Retinal detachments were more likely in patients with a gestational age of 29 weeks or less (P < 0.05) and in eyes with furthest vascularization to posterior zone 2 eyes compared with zone 3 eyes (P = 0.009).

conclusionsEyes with ROP not meeting the treatment threshold during infancy showed various late retinal findings and complications, of which RDs were the most concerning. Complications were seen in all age groups, including patients born after the Early Treatment for Retinopathy of Prematurity Study. Contributing factors to RDs included atrophic holes within peripheral avascular retina, visible vitreous condensation ridge-like interface with residual traction, and premature vitreous syneresis. We recommend regular examinations and consideration of ultra-widefield FA examinations. Prospective studies are needed to explore the frequency of complications and benefit of prophylactic treatment and if eyes treated with anti-vascular endothelial growth factor therapy are at risk of similar findings and complications.

Indexed as

Visual AcuityAdolescentAdultAgedChildDisease ProgressionFemaleFluorescein AngiographyFundus OculiHumansMaleMiddle AgedRetinaRetinal DetachmentRetinal PerforationsRetinopathy of Prematurity

Identifiers

PMID32059986
PMCPMC7282927
OpenAlexW2998430743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.